The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
Its builders believe that it is one of the largest public-sector IT systems in the world. Given that most national ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback